|
WO2021079253A1
|
|
Composition for the cardiovascular risk reduction
|
|
WO2021019434A1
|
|
Composition for use in the prevention and/or treatment of symptoms related to tiredness and fatigue
|
|
WO2020234770A1
|
|
Composition for use in the prevention and/or treatment of pathologies associated to the prostate
|
|
WO2020222166A1
|
|
Composition for the prevention and treatment of urinary stones
|
|
WO2020128939A1
|
|
Composition for the treatment of female sexual dysfunctions
|
|
WO2020104987A1
|
|
Composition for use in the prevention and/or symptomatic treatment of irritable bowel syndrome
|
|
WO2020064370A1
|
|
Composition for the prevention and treatment of diseases of the respiratory system
|
|
WO2020053783A1
|
|
A composition for use in the prevention and/or treatment of epistaxis
|
|
WO2020003106A1
|
|
Composition for use in the prevention and/or treatment of osteoarticular diseases
|
|
WO2020002161A1
|
|
Composition for the prevention and treatment of cardiovascular diseases
|
|
EP3810108A1
|
|
Composition for use in the prevention and/or treatment of osteoarticular diseases
|
|
WO2019243991A1
|
|
Composition for gastric and oesophageal diseases
|
|
IT201900002623A1
|
|
Composition for the prevention and / or treatment of diseases of the oropharyngeal mucosa
|
|
WO2019215174A1
|
|
Composition for the prevention and treatment of skin aging
|
|
IT201900000484A1
|
|
Composition for the treatment of disorders affecting the female urogenital system
|
|
WO2019180635A1
|
|
Composition fo use for the treatment of respiratory and oropharyngeal diseases
|
|
EP3545947A1
|
|
Composition for the reduction of plasma levels of uric acid
|
|
WO2019141540A1
|
|
Composition for the treatment of diseases of the respiratory tract
|
|
EP3723734A1
|
|
Composition for the treatment of alopecia
|
|
WO2019102437A1
|
|
Composition for preventing and/or curing gastrointestinal disorders
|
